ReviewCell & bioscience2021
Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy.
Review in Cell & bioscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Interleukin-22 reflects adverse cardiometabolic features in SLE.Lupus science & medicine · 2026Article
- IL-22 Associates with Venous Thromboembolism in Inflammatory Bowel Disease: A Hypothesis-Generating Study.Digestion · 2026Article
- Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancerWorld journal of gastrointestinal oncology · 2025Article
- Article
- Exploring association of melanoma-specific Bcl-xL with tumor immune microenvironment.Journal of experimental & clinical cancer research : CR · 2023Article
- Relationship between IL-22 and IL-22BP in diabetic cognitive dysfunction.Acta diabetologica · 2023Article
- Microbiota as key factors in inflammatory bowel disease.Frontiers in microbiology · 2023Review
- Cellular mechanisms linking to outdoor and indoor air pollution damage during pregnancy.Frontiers in endocrinology · 2023Review
- Quantitative assessment of left ventricular myocardial involvement in patients with connective tissue disease: a 3.0T contrast-enhanced cardiovascular magnetic resonance study.The international journal of cardiovascular imaging · 2022Article
- Transcription Factor AhR, Cytokines IL-6 and IL-22 in Subjects with and without Peri-Implantitis: A Case Control-Study.International journal of environmental research and public health · 2022Article
- IL-22 regulates endometrial regeneration by enhancing tight junctions and orchestrating extracellular matrix.Frontiers in immunology · 2022Article
- The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications.Cells · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Interleukin-22 (IL-22), a member of the IL-10 family of cytokines, is produced by a number of immune cells involved in the immune microenvironment of the body. IL-22 plays its pivotal roles by binding to the IL-22 receptor complex (IL-22R) and subsequently activating the IL-22R downstream signalling pathway. It has recently been reported that IL-22 also contributes to the pathogenesis of many connective tissue diseases (CTDs). In this review, we will discuss the role of IL-22 in several CTDs, such as system lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, systemic sclerosis and dermatomyositis, suggesting that IL-22 may be a potential therapeutic target in CTDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.